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Background: Peptide nucleic acid fluorescent in situ hybridization (PNA-FISH) is a rapid and established method for
identification of Candida sp., Gram positive, and Gram negative bacteria from positive blood cultures. This study
reports clinical experience in the evaluation of 103 positive blood cultures and 17 positive peritoneal fluid cultures
from 120 patients using PNA-FISH. Our study provides evidence as to potential pharmaceutical cost savings based
on rapid pathogen identification, in addition to the novel application of PNA-FISH to peritoneal fluid specimens.
Methods: Identification accuracy and elapsed time to identification of Gram positives, Gram negatives, and Candida
sp., isolated from blood and peritoneal fluid cultures were assessed using PNA-FISH (AdvanDx), as compared to
standard culture methods. Patient charts were reviewed to extrapolate potential pharmaceutical cost savings due to
adjustment of antimicrobial or antifungal therapy, based on identification by PNA-FISH.
Results: In blood cultures, time to identification by standard culture methods for bacteria and Candida sp.,
averaged 83.6 hours (95% CI 56.7 to 110.5). Identification by PNA-FISH averaged 11.2 hours (95% CI 4.8 to 17.6).
Overall PNA-FISH identification accuracy was 98.8% (83/84, 95% CI 93.5% to 99.9%) as compared to culture. In
peritoneal fluid, identification of bacteria by culture averaged 87.4 hours (95% CI −92.4 to 267.1). Identification by
PNA-FISH averaged 16.4 hours (95% CI −57.3 to 90.0). Overall PNA-FISH identification accuracy was 100% (13/13,
95% CI 75.3% to 100%). For Candida sp., pharmaceutical cost savings based on PNA-FISH identification could be
$377.74/day. For coagulase-negative staphylococcus (CoNS), discontinuation of vancomycin could result in savings
of $20.00/day.
Conclusions: In this retrospective study, excellent accuracy of PNA-FISH in blood and peritoneal fluids with
reduced time to identification was observed, as compared to conventional culture-based techniques. Species-level
identification based on PNA-FISH could contribute to notable cost savings due to adjustments in empiric
antimicrobial or antifungal therapy as appropriate to the pathogen identified.
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Rapid identification of pathogens in blood and peritoneal
fluid plays a critical role in patient outcomes, and health-
care cost. Bloodstream associated infections (BSI) are the
10th leading cause of death in the U.S [1]; this rate has
increased by 78% over the last 2 decades. Bloodstream
infections acquired in hospitals account for approximately* Correspondence: hata.donna@mayo.edu
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reproduction in any medium, provided the or250,000 cases each year with a direct attributable mortality
rate of 16-40%. Total hospitalization time is prolonged by
4.5-32 days [2], and inappropriate empirical antimicrobial
therapy is an important predictor of death in this patient
population [3].
In identification of organisms implicated in BSI, auto-
mated blood culture followed by biochemical analysis of
isolates is considered the gold standard [4]. New detec-
tion technologies for organism identification from blood
culture such as real-time PCR, DNA microarrays,
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acid fluorescent in situ hybridization (PNA-FISH) for
detection of Candida, Gram positive, and Gram negative
organisms may increase organism identification accuracy,
and significantly reduce time to result [5].
PNA-FISH is a U.S. Food and Drug Administration
(FDA) approved commercially available method for the
detection of bacteria and yeast species directly from
positive blood culture bottles. This methodology utilizes
hybridization of PNA probes to organism-specific rRNA,
with detection via fluorescent microscopy [6,7]. To date,
studies utilizing PNA-FISH have been reported for de-
tection of Gram positive organisms, Candida, and other
Gram negative species [3,8-12]. Although not specifically
FDA-approved for this indication, our study also
assessed identification accuracy from peritoneal fluid
inoculated into blood culture media. We are unaware of
other published studies evaluating PNA-FISH for identi-
fying organisms from peritoneal fluid.
The purpose of our study was to compare PNA-FISH
to traditional culture techniques in blood and peritoneal
fluids for accuracy in identification to species, and over-
all time to identification of Gram positive organisms,
Gram negative organisms and Candida spp. In a sec-
ondary analysis, we specifically examined the potential
pharmaceutical cost savings when the correct species of
Candida was identified with concomitant correction of
antifungal therapy as necessary. This manner of analysis
was also applied to vancomycin costs when identification
of coagulase-negative Staphylococcus (CoNS) was achieved
by PNA-FISH in blood cultures.
Methods
This study was approved by the Mayo Clinic Institu-
tional Review Board. This study retrospectively evaluated
blood or peritoneal fluid cultures from 120 patients rou-
tinely submitted to the Clinical Microbiology Laboratory
at Mayo Clinic in Jacksonville, FL from February through
June 2009. Testing was performed using both traditional
blood culture methodology and PNA-FISH (AdvanDx,
Woburn, MA). PNA-FISH testing and standard blood
culture workup was performed by two different tech-
nologists, with reciprocal blinding of results.
Blood/peritoneal fluid cultures
Blood cultures and peritoneal fluid cultures were per-
formed using BACTEC Plus Aerobic F and Plus Anaerobic
F bottles (Becton Dickinson, Sparks, MD) using standard
methods and according to the manufacturer’s recommen-
dations [4]. As part of a routine culture set consisting of
one aerobic and one anaerobic bottle, 8.0 to 10.0 mL of
blood or peritoneal fluid were inoculated in each BACTEC
bottle and incubated at 37°C. When the first bottle of the
pair signaled positive by the BACTEC 9240 instrumentand confirmed by Gram stain, an aliquot from the bottle
was subcultured to a blood agar plate and incubated at
37°C. After sufficient pure bacterial growth was
achieved (24 – 88 hours), identification tests were per-
formed on a Microscan Walkaway-96 system utilizing a
24 hour incubation period using GP-33 or GN-34 com-
bination panels as appropriate (Siemens Healthcare
Diagnostics, Deerfield IL).
PNA-FISH
Blood culture bottles signaling positive in the BACTEC
system were tested on the same day with PNA-FISH.
Based on Gram stain results from the signal-positive
blood culture bottle, a specific PNA-FISH probe was
selected for use. These consisted of the S. aureus/CoNS,
E. faecalis/OE (other Enterococci, E. faecium), E. coli/P.
aeruginosa, EK (E. coli, K. pneumoniae/P. aeruginosa).
For yeasts, probes for C. albicans/C. glabrata, and the
Yeast Traffic Light (C. albicans/C. parapsilosis - green,
C. glabrata/C. krusei - red, C. tropicalis – yellow) were
utilized. The PNA-FISH method was performed accord-
ing to manufacturer’s recommendations. One drop of
fixation solution was gently mixed with one drop (10 μl)
of specimen from a positive BACTEC bottle on a PNA-
FISH slide. Slides were fixed in methanol, followed by
immersion in 80% ethanol for 10 minutes. Slides were
allowed to air dry. One drop of specific PNA probe mix-
ture was applied to the slide, a cover slip was applied,
and the slide was hybridized for 90 minutes at 55°C.
Post-hybridization, slides were incubated in 55°C wash
solution for 30 minutes. Slides were allowed to air dry,
and mounted. Slides were examined at 60X on an
Olympus BX-41 fluorescent microscope equipped with
a 528-633λ dual band filter. Slides were examined for
the presence of multiple bright fluorescent (green, red,
yellow), morphologically consistent microorganisms in
multiple fields of view. Organisms resembling yeast
were initially tested with the C. albicans/C. glabrata
PNA-FISH probe. If negative, PNA-FISH was repeated
with the Yeast Traffic Light probe in order to identify
presence of C. parapsilosis, C. krusei, or C. tropicalis.
Gram-negative organisms were initially tested with the
E. coli/P. aeruginosa probe. If negative, PNA-FISH was
repeated with the EK/P. aeruginosa probe in order to
identify presence of Klebsiella pneumoniae.
Probe-specific PNA-FISH positive and negative control
slides were obtained from the manufacturer and utilized
for quality control each time PNA-FISH was performed.
All bacterial and yeast identifications from blood and
peritoneal fluid cultures were confirmed using standard
methods by the Clinical Microbiology Laboratory at
Mayo Clinic in Jacksonville, FL.
Identification accuracy and time to identification using
both PNA-FISH and culture (gold standard) were
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calculated from the time the BACTEC bottle signaled
positive, to the time at which the microbiology labora-
tory identified the organism. Time to identification with
PNA-FISH (F-ID) was calculated from the time the
BACTEC bottle initially signaled positive, to completion
of F-ID. Appropriate controls were performed with each
PNA-FISH test batch. PNA-FISH was performed in
batches twice daily at 8am and 1pm. All samples that be-
came BACTEC positive between those times were heldFigure 1 Analysis of Blood Culture by PNA-FISH.until the next processing period, and the time elapsed
until processing was added to the total F-ID time. Time
saved was defined as the difference between C-ID and
F-ID. Organisms that could not be identified by PNA-
FISH were not included in C-ID or F-ID calculations.
In order to better assess detection and identification of
Candida spp., 15 BACTEC bottles were spiked (9 blood,
6 peritoneal fluid) by mixing 8.0 mL of culture-negative
blood or peritoneal fluid with 2.0 mL of a 0.5 McFarland
suspension of a known species of yeast and inoculating
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ard conditions until they signaled positive. At that time
the bottle was removed from the BACTEC instrument
and processed as previously described. The results from
these spiked bottles were included only in the accuracy
calculations, and not calculated time to detection. Statis-
tical significance of time to C-ID versus time to F-ID
was calculated using t test method and GraphPad [13].
Patient charts were reviewed for selection of empiric
antimicrobial in order to extrapolate potential pharma-
ceutical cost savings of PNA-FISH. Pharmaceutical costs
were based on the 2009 institutional Average Wholesale
Price (AWP). The AWP for oral fluconazole 400 mg
daily was $27.26, and caspofungin 50 mg daily was
$405.00. The AWP of IV vancomycin 2 grams daily was
$20.00 [14].
Results
A total of 103 blood culture bottles and 17 peritoneal
fluid culture bottles were signal-positive for bacterial or
fungal growth after incubation in the BACTEC system.
Of those, 9 blood and 6 peritoneal fluid culture bottles
had been spiked with Candida sp. or other yeasts in the
laboratory in order to increase sample numbers to statis-
tically meaningful levels specific for the pathogen. Com-
pared to traditional culture methods, 96 of 120 positive
BACTEC blood culture bottles contained an organismFigure 2 Analysis of Peritoneal Fluid Cultures by PNA-FISH.for which a PNA-FISH probe was available. Twenty-
three signal-positive bottles contained a bacteria or yeast
for which a PNA-FISH probe was not available [Figure 1,
Figure 2]. All 23 of these bottles tested negative by
PNA-FISH probes used in this study.
In signal-positive blood culture bottles containing
Gram positive bacteria, the following species were iden-
tified by PNA-FISH: 34 coagulase-negative Staphylococ-
cus [CoNS], 10 S. aureus, 5 E. faecalis, 5 E. faecium. In
signal-positive blood culture bottles containing Gram
negative bacteria, the following species were identified: 9
E. coli, 5 K. pneumoniae, 5 P. aeruginosa. In signal posi-
tive blood culture bottles containing yeasts, the follow-
ing species were identified: 8 C. albicans, 1 C. glabrata,
1 C. parapsilosis. One isolate from a positive blood cul-
ture bottle confirmed as C. albicans reacted only weakly
with the C. albicans/C. glabrata dual probe as well as
the PNA-FISH Traffic Light, and was judged to be nega-
tive by PNA-FISH. Of the 9 blood culture bottles spiked
with yeasts; 7 positive bottles containing C. albicans
were correctly identified by PNA-FISH. Two spiked bot-
tles contained a yeast for which a PNA-FISH probe was
not available (C. pelliculosa, Cr. neoformans); both bot-
tles were negative with the yeast dual probe and Traffic
Light probe [Figure 1]. Spiked bottles were included for
accuracy calculations, but not included in calculation of
time to results.
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Gram positive organisms were identified 70.2 hours
faster with PNA-FISH (95% CI 60.2 to 80.3, p< 0.0001)
and Gram negative organisms were identified 64.1 hours
more rapidly (95% CI 51.0 to 77.2, p =0.0002). Candida sp.
were identified 83.0 hours faster with PNA-FISH compared
to culture (95% CI 33.8 to 132.3 p=0.0095) [Table 1]. ForTable 1 Time to Identification of isolates from blood and per
BLOOD CU
Organism N Mean Culture
Hours to ID (range)
Mean
Hours t
All Gram Positive 54 78.5 h
(20–112) (
CoNS 34 72.2 1
(20–103) (3
S. aureus 10 79.0 h
(47 – 98) (
E. faecalis 5 73.8 h





All Gram Negative 19 76.2 h 1
(23 –112) (3
E. coli 9 78.4 h
(25 –108) (5
K. pneumoniae 5 71.6 h 1
(23 –112) (5
P. aeruginosa 5 70.0 h
(40–94) (3
All Candida 4 96.0 h 1
(72 –130) (7.2
C. albicans 2* 72.0 h
C. glabrata 1 130 h 1
C. parapsilosis 1 86 1
PERITONEAL FLU
All Gram Positive 5 73.2 h 1
(23–111) (2
CoNS 1 111.0 h 1




2 92.5 h 1
(75 – 110) (5
All Gram Negative 2 101.5 h 2
K. pneumoniae 2 101.5 h 2
(90 – 113)
* One isolate not identified by PNA-FISH.
† PNA-FISH is not FDA approved for this sample type.
‡ Not statistically significant.bacteria, overall accuracy of identification with PNA-FISH
compared to culture was 100% (73/73, 95% CI 95% to
100%). Overall accuracy of Candida sp. identification was
90.9% (10/11, 95% CI 58.7% to 99%).
Results from peritoneal fluid cultures were analyzed
separately from blood cultures due to potential differ-







8.3 h 70.2 h <0.0001
3–22) (1 – 94)
2.5 h 59.7 h <0.0001
– 22) (1 – 93)
9.9 h 65.8 h <0.0001
3–20) (33 – 93)
5.8 h 68.0 h <0.0001
– 15) (45 – 94)
6.4 h 82.6 h <0.0001
– 20) (69 – 93)
2.1 h 64.1 h 0.0002
– 24) (3–115)
9.2 h 69.4 h <0.0001
– 18) (20 – 91)
7.8 h 54.0 h 0.0109
– 24) (3 – 91)
7.8 h 58.8 h 0.0002
– 22) (18 – 90)
3.2 h 83.0 h 0.0095
– 17.2) (65 – 115)
7.2 h 64.8 h N/A
5.2 h 114.8 h N/A
7.2 h 68.8 h NA
ID CULTURES†
0.6 h 62.6 h 0.0070
– 22.2) (21 – 90.8)
9.6 h 91.4 h N/A
4.5 h 30.5 0.1306‡
2 – 7) (21 – 40)
2.1 h 80.h 0.0522‡
– 20) (70 – 90)
2.2 h 79.3 h 0.0204
2.2 h 79.3 h 0.0204
(22.2) (67.8 – 90.8)
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positive for bacterial growth. Among signal-positive
blood culture bottles containing Gram positive bacteria,
the following species were identified: 2 E. faecalis, 2 E.
faecium, 1 CoNS. Four bottles contained Streptococcus
viridans, and subsequently could not be identified by
PNA-FISH. Two signal-positive bottles contained Gram
negative bacteria; 2/2 isolates were identified as K. pneu-
moniae by PNA-FISH. During the period of the study,
no peritoneal infections with Candida sp. were noted
among clinical specimens submitted to the laboratory.
Among the 6 peritoneal fluid bottles spiked with Can-
dida sp. (3 C. albicans, 2 C. glabrata, 1 C. tropicalis) all
species were correctly identified by PNA-FISH [Figure 2].
Results from spiked bottles were included only in the ac-
curacy calculation; comparative time to detection was
not calculated. Gram positive organisms were identified
62.6 hours faster with PNA-FISH compared to culture
(95% CI 2.8 to 132.1, p=0.0070) and Gram negative
organisms were identified 79.3 hours faster with PNA-
FISH (95% CI 29.82 to 128.78, p=0.0204) [Table 1].
Overall mean time saved using PNA-FISH for detection
of Gram positive and Gram negative organisms in peri-
toneal fluid cultures was 70.95 hours (95% CI 5.2 to
136.7, p=0.0435). The overall accuracy for detection of
bacteria and Candida sp. in peritoneal fluid was 100%
(6/6, 95% CI 54% to 100%). During testing of blood and
peritoneal fluids, all PNA-FISH control slides performed
as expected, thus the inter-run precision of the test was
100%.
Projected pharmaceutical costs
Antifungal/antimicrobial costs were extrapolated based
on organism identification from blood, time to identifi-
cation, and chart review of therapy [Table 2]. In 2 of 3










1 C. albicans Caspofungin 6 3




1 CoNS Vancomycin 3 3.7
2 CoNS Vancomycin 4 2.1
3 CoNS Vancomycin 5 3.2
4 CoNS Vancomycin 2 0.8
† Potential time saved w/PNA-FISH X AWP = Potential cost saved w/PNA-FISH.
AWP:
Fluconazole 400mg po/day= $27.26.
Caspofungin 50mg IV/day=$405.00.
Vancomycin 2 g/day=$20.00.available, two patients were empirically treated with cas-
pofungin for suspected C. glabrata fungemia. When iden-
tification was finalized by conventional methods as C.
albicans and C. parapsilosis, therapy was changed to flu-
conazole. Using PNA-FISH, identification of C. albicans
and C. parapsilosis could have been achieved in an average
of 1/2 day, compared to 4 days with C-ID, resulting in
potential antifungal cost savings due to change of therapy
from caspofungin to fluconazole of $377.74 per day.
Four patients were selected for chart review in order
to determine the potential effect of time to culture result
on antibiotic costs. Each case tested positive for CoNS
in blood cultures by C-ID and F-ID. Upon initial positive
blood culture, patients were treated with vancomycin
until culture identification of CoNS by C-ID was veri-
fied. At that point, based on clinical presentation, CoNS
was considered a contaminant, resulting in discontinu-
ation of vancomycin therapy. The time to result by C-ID
was compared to the time to result by F-ID, and poten-
tial time to result saved by F-ID calculated. In this small
subset of patients, the use of PNA-FISH, for rapid iden-
tification of CoNS, could have resulted in discontinu-
ation of IV vancomycin an average of 2.2 days earlier,
with an estimated savings of $20.00/day [Table 2].
Discussion
PNA-FISH has been shown to be a useful and accurate
method in the identification of Gram positive, Gram
negative, and Candida sp. from blood cultures and peri-
toneal fluid cultures. When analyzing PNA-FISH probe
performance for both bacteria and yeast combined in
both sample types, we demonstrated an overall identifi-
cation accuracy of 98.9% (96/97). Accuracy of PNA-FISH
for bacteria was 100% (80/80), accuracy for Candida sp.
was 94.1% (16/17). This high level of accuracy with PNA-
FISH has been replicated in other studies [6-10,12,15]. WeTime to PNA-
FISH ID (days)
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bottles, as PNA-FISH requires an organism concentration
of at least 105 CFU/mL for detection.
Clinical isolates identified in this study are representa-
tive of the most commonly reported pathogens impli-
cated in nosocomial bloodstream infections in the
United States [2]. In blood cultures, accuracy of PNA-
FISH for bacteria was 100%. In this study, accuracy for
yeast identification was 90.9% (10/11). A single weakly
reactive C. albicans isolate may have been due to a mis-
match between organism rRNA and PNA-FISH probe
secondary to point mutations in sequence, as have been
described by other authors [11,12].
Mean time saved using PNA-FISH for blood cultures
compared to traditional culture methods averaged 72.4
hours from the time the organism (bacteria or yeast)
was detected by Gram stain from a positive blood cul-
ture bottle until final identification of species [Table 1].
The significant difference in time of C-ID as compared
to F-ID may partially be attributed to conventional la-
boratory workflow with C-ID; after subculture of a posi-
tive blood culture bottle, plate cultures were assessed
once daily for adequate growth. Panels used for auto-
mated bacterial identification were set up once daily if
plate culture growth was sufficient followed by 24-hour
incubation. An advantage of the PNA-FISH method-
ology is ease of use, in that multiple final identifications
may be generated in a single laboratory shift directly
from positive blood culture bottles, without need for
additional incubation.
The use of blood culture media is a useful method of
enhancing recovery of microorganisms from peritoneal
fluids [16-18]. Although not specifically FDA-approved
for this indication, we also assessed performance of
PNA-FISH using peritoneal fluid specimens incubated in
blood culture bottles, as proof of concept. To the best of
our knowledge this study is the first application of this
PNA-FISH method for this sample type. Identification
accuracy for both bacteria and Candida sp. was 100%.
Although mean time saved with PNA-FISH was not
significant for Enterococcus sp., this was likely attribut-
able to low sample numbers (Table 1).
Laboratory-spiked bottles were not used for turn-
around time determination for Candida sp. in peritoneal
fluids, as the intent of the study was to mimic actual
clinical performance of PNA-FISH from blood culture
media as much as possible. Although the turnaround
time for Candida sp. could not be specifically deter-
mined due to the use of spiked bottles, based on blood
culture data, it is reasonable to assume a similar reduc-
tion in time to F-ID in peritoneal fluid samples would
also apply. Low numbers of peritoneal fluids tested is a
limitation of this study. Although blood culture bottles
containing peritoneal fluid spiked with Candida sp. wereused to increase numbers to statistically meaningful
levels, every attempt was made to apply PNA-FISH to
situations found in actual clinical practice. Excellent per-
formance of PNA-FISH with this sample type is encour-
aging for application to larger scale studies required to
truly assess assay performance.
Accurate identification of pathogens is a primary
driver of antimicrobial or antifungal selection. Delays in
appropriate therapy clearly affect patient outcomes in a
negative fashion. Among 492 intensive care patients
studied by Ibrahim et al., 30% received inadequate anti-
microbial therapy for bacteremia; hospital mortality rate
was 62% compared to 28.4% of patients receiving appro-
priate antibiotics [3]. In terms of yeast identification,
both SENTRY and EIEIO sentinel surveillance programs
demonstrated a shift in pathogenic Candida species over
the last decade [19]. These findings support the import-
ance of rapid identification of yeast to species level as
critical to direct appropriate antifungal therapy. Excel-
lent performance by PNA-FISH in both bacteria and
yeast will address these clinical needs.
In this study, based on a limited chart review of clinical
cases, the more expensive antifungal caspofungin was
used empirically for 5–6 days in 2 cases in which the
organism was C. albicans or C. parapsilosis fully suscep-
tible to fluconazole. Based on our estimated antifungal
cost savings, and 2009 AWP data, this could potentially
result in pharmaceutical cost savings of $1,888.70 over 5
days of therapy. Significant pharmaceutical cost savings
due to de-escalation of therapy from an echinocandin to
fluconazole in infections caused by fluconazole –suscep-
tible C. glabrata have also been noted in other studies [20].
We also examined the costs associated with the use of
vancomycin for CoNS infection. In four cases in which
chart review was available, empiric therapy with vanco-
mycin was continued for 2–5 days and not discontinued
until CoNS was identified and deemed a contaminant,
based on clinical presentation of the patient. Avoiding
unnecessary use of vancomycin in these instances could
save an estimated $20.00 daily per patient. Based on our
study, and use of PNA-FISH, more appropriate use of
vancomycin and caspofungin could reduce hospital
pharmaceutical costs. As indicated in other studies,
rapid organism identification and judicious use of anti-
biotics has overall broader implications in antibiotic
stewardship and may positively affect reduction of anti-
biotic resistance and patient mortality [6,8,21].
Based upon chart review, a disparity was noted be-
tween time of C-ID or F-ID, and the time of therapy ini-
tiation until a change in therapy was made based on ID
results (Table 2). We cannot specifically comment why,
in some cases, antifungal or antibiotic therapy was not
changed after organism ID was finalized. This obviously
affects overall estimates of pharmaceutical cost. Based
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that if patients are improving under a given course of
therapy, clinicians are less likely to change therapy, even
with the availability of ID results. Proactive management
of identification results by stakeholders such as Infec-
tious Disease or Pharmacy, as part of an active antibiotic
stewardship program will contribute to the downstream
benefits of rapid diagnosis by PNA-FISH.
A limitation of PNA-FISH is a requirement of an or-
ganism concentration of at least 105 CFU/mL for detec-
tion. This requirement may prove to be problematic for
detection of slow-growing, or fastidious organisms. At
the time this study was performed, a limited number of
PNA-FISH probes were available. However, additional
specific PNA-FISH probes are now available for Group
B Streptococcus , GNR Traffic Light (FDA-approved), C.
dubliniensis, C. parapsilosis, K. pneumoniae, and Acine-
tobacter (analyte-specific reagents). Recent FDA ap-
proval of a more rapid PNA-FISH protocol should prove
to be advantageous in further decreasing turnaround
time to organism identification [9].
Conclusion
This study expands the body of knowledge evaluating
PNA-FISH, a useful method for identification of organ-
isms directly from blood culture bottles. Our study
demonstrated excellent accuracy of identification of
organisms for which PNA-FISH probes were available.
This includes the most commonly isolated species impli-
cated in bacteremia and fungemia. In addition, success-
ful use of PNA-FISH in peritoneal fluid cultures could
be extremely beneficial in analysis of this sample type.
Turnaround time for final identification from both blood
cultures and peritoneal fluid was significantly reduced in
comparison to traditional culture methods. A recently
approved shortened hybridization protocol will further
contribute to a reduction in laboratory turnaround time.
Although the correct choice of a PNA-FISH probe is
contingent upon correct interpretation of a Gram stain,
we do not feel this is an issue with properly trained la-
boratory technologists. PNA-FISH is easy to perform in
the clinical laboratory and does not require significant
capital equipment costs unlike microarrays or MALDI-
TOF. PNA-FISH requires a microscope equipped with a
fluorescent lamp and dual band filters for interpretation
of results. Of primary importance, the accuracy and spe-
cificity of PNA-FISH can significantly affect antibiotic
and antifungal utilization, allowing for more targeted
therapy, reduction of duration of therapy, with an overall
reduction of healthcare costs, and increased benefit to
patients.
Abbreviations
PNA-FISH: Peptide nucleic acid fluorescent in situ hybridization;
BSI: Bloodstream associated infections; MALDI-TOF: Matrix-assisted laserdesorption ionization time of flight mass spectrometry; CoNS: Coagulase-
negative Staphylococcus; C-ID: Time to identify with culture; F-ID: Time to
identify with PNA-FISH; AWP: Average wholesale price.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DMH performed laboratory testing, data acquisition, chart review and
pharmaceutical cost analysis. DJH contributed to study design, data analysis,
and result interpretation. All authors contributed to the preparation of the
manuscript. All authors have read and approved the final manuscript.
Previous presentations
This study was presented in part at the 49th Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept. 12 – 15,
2009
Acknowledgements
We would like to acknowledge Aaron Odegard, the Clinical Microbiology
Laboratory at Mayo Clinic in Jacksonville, FL, and the Mycology Laboratory at
Mayo Clinic in Rochester, MN for technical assistance. We would also like to
acknowledge BioMérieux, Inc. and AdvanDx Inc. for supplying testing
equipment and test kits.
Author details
1Division of Hospital Internal Medicine, Mayo Clinic College of Medicine,
4500 San Pablo Rd, Jacksonville, Florida 32224, USA. 2Department of
Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 4500
San Pablo Rd, Jacksonville, Florida 32224, USA.
Received: 13 December 2012 Accepted: 5 January 2013
Published: 7 January 2013
References
1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B: Deaths:
final data for 2006. Natl Vital Stat Rep 2009, 57(14):1–134.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB:
Nosocomial bloodstream infections in US hospitals: analysis of 24,179
cases from a prospective nationwide surveillance study. Clin Inf Dis 2004,
39(3):309–317.
3. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH: The influence of
inadequate antimicrobial treatment of bloodstream infections on patient
outcomes in the ICU setting. Chest 2000, 118(1):146–155.
4. Baron EJ, Weinstein MP, Dunne WMJ, Yagupsky P, Welch DF, Wilson DM:
Cumitech 1C: Blood Cultures IV. 1st edition. Washington D.C: ASM Press; 2005.
5. Klouche M, Schroder U: Rapid methods for diagnosis of bloodstream
infections. Clin Chem Lab Med 2008, 46(7):888–908.
6. Forrest GN, Roghmann MC, Toombs LS, Johnson JK, Weekes E, Lincalis DP,
Venezia RA: Peptide nucleic acid fluorescent in situ hybridization for
hospital-acquired enterococcal bacteremia: delivering earlier effective
antimicrobial therapy. Antimicrob Agents Chemother 2008,
52(10):3558–3563.
7. Sogaard M, Hansen DS, Fiandaca MJ, Stender H, Schonheyder HC: Peptide
nucleic acid fluorescence in situ hybridization for rapid detection of
Klebsiella pneumoniae from positive blood cultures. J Med Microbiol 2007,
56(Pt 7):914–917.
8. Forrest GN, Mehta S, Weekes E, Lincalis DP, Johnson JK, Venezia RA: Impact
of rapid in situ hybridization testing on coagulase-negative
staphylococci positive blood cultures. J Antimicrob Chemother 2006,
58(1):154–158.
9. Morgan M, Marlowe E, Della-Latta P, Salimnia H, Novak-Weekley S, Wu F,
Crystal BS: Multicenter evaluation of a new shortened peptide nucleic
acid fluorescence in situ hybridization procedure for species
identification of select Gram-negative bacilli from blood cultures. J Clin
Microbiol 2010, 48(6):2268–2270.
10. Reller ME, Mallonee AB, Kwiatkowski NP, Merz WG: Use of peptide nucleic
acid-fluorescence in situ hybridization for definitive, rapid identification
of five common Candida species. J Clin Microbiol 2007, 45(11):3802–3803.
11. Rigby S, Procop GW, Haase G, Wilson D, Hall G, Kurtzman C, Oliveira K, Von
Oy S, Hyldig-Nielsen JJ, Coull J, et al: Fluorescence in situ hybridization
Harris and Hata Annals of Clinical Microbiology and Antimicrobials 2013, 12:2 Page 9 of 9
http://www.ann-clinmicrob.com/content/12/1/2with peptide nucleic acid probes for rapid identification of
Candida albicans directly from blood culture bottles. J Clin Microbiol 2002,
40(6):2182–2186.
12. Shepard JR, Addison RM, Alexander BD, Della-Latta P, Gherna M, Haase G,
Hall G, Johnson JK, Merz WG, Peltroche-Llacsahuanga H, et al: Multicenter
evaluation of the Candida albicans/Candida glabrata peptide nucleic
acid fluorescent in situ hybridization method for simultaneous dual-
color identification of C. albicans and C. glabrata directly from blood
culture bottles. J Clin Microbiol 2008, 46(1):50–55.
13. GraphPad Software QuickCalcs. http://graphpad.com/quickcalcs.
14. Book R: Pharmacy Fundamental Reference. 113th edition. Montvale, New
Jersey: Physicians Desk Reference Inc; 2009.
15. Hall L, Le Febre KM, Deml SM, Wohlfiel SL, Wengenack NL: Evaluation of
the Yeast Traffic Light PNA FISH probes for identification of Candida
species from positive blood cultures. J Clin Microbiol 2012,
50(4):1446–1448.
16. Akcam FZ, Yayli G, Uskun E, Kaya O, Demir C: Evaluation of the Bactec
microbial detection system for culturing miscellaneous sterile body
fluids. Res Microbiol 2006, 157(5):433–436.
17. Fuller DD, Davis TE: Comparison of BACTEC plus Aerobic/F, Anaerobic/F,
Peds Plus/F, and Lytic/F media with and without fastidious organism
supplement to conventional methods for culture of sterile body fluids.
Diagn Microbiol Infect Dis 1997, 29(4):219–225.
18. Sorlin P, Mansoor I, Dagyaran C, Struelens MJ: Comparison of resin-
containing BACTEC Plus Aerobic/F* medium with conventional methods
for culture of normally sterile body fluids. J Med Microbiol 2000,
49(9):787–791.
19. Pfaller MA, Diekema DJ: Role of sentinel surveillance of candidemia:
trends in species distribution and antifungal susceptibility. J Clin
Microbiol 2002, 40(10):3551–3557.
20. Collins CD, Eschenauer GA, Salo SL, Newton DW: To test or not to test: a cost
minimization analysis of susceptibility testing for patients with documented
Candida glabrata fungemias. J Clin Microbiol 2007, 45(6):1884–1888.
21. Hermsen ED, Shull SS, Klepser DG, Iwen PC, Armbrust A, Garrett J, Freifeld
AG, Rupp ME: Pharmacoeconomic analysis of microbiologic techniques
for differentiating staphylococci directly from blood culture bottles. J Clin
Microbiol 2008, 46(9):2924–2929.
doi:10.1186/1476-0711-12-2
Cite this article as: Harris and Hata: Rapid identification of bacteria and
candida using pna-fish from blood and peritoneal fluid cultures: a
retrospective clinical study. Annals of Clinical Microbiology and
Antimicrobials 2013 12:2.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
